In an article published in Frontiers in Pharmacology, researchers made recommendations to improve the biosimilar regulatory system and refine biosimilar guidelines in China.
Researchers have made recommendations to improve the biosimilar regulatory system and refine biosimilar guidelines in China, in a new article published in Frontiers in Pharmacology.
Although China has the highest number of biosimilar drugs under research in the world (N = 391), laws and regulations for biosimilars in China, including a complete registration management system and supervision policies, are not “clearly formed.” As of the end of 2020, there have been 11 biosimilars approved for the Chinese market.
“There is an urgent need for a corresponding regulatory system for biosimilar drugs. While developing the laws and regulatory system, efforts should be made to avoid any deviations that happened in the evaluation of chemical generics and should focus on completing the task in hand in one attempt,” the authors wrote.
The following recommendations were suggested:
For identifying and obtaining reference drugs, the authors recommended that reference drugs be purchased from the Chinese market or the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) national markets approved by China.
Regarding managing labels, it’s difficult to ensure that the macromolecular structural characteristics of biosimilars are consistent with the reference biologics. Labels should state that the product is a biosimilar and include comparative safety and efficacy data “to provide sufficient information for clinicians to make prescription decisions," the authors wrote.
The authors exercised caution with indication extrapolation, saying that “extrapolated indications should be those approved for marketing in China in order to reduce the unknown risks posed by ethnic differences…declaration of all indications of the original biological products should be encouraged when marketed in China, in order to provide a reference basis for the extrapolation of the indications of their biosimilar drugs.”
When naming biosimilars, the authors recommended that biosimilars should have distinct names to attract the attention of clinicians, noting that although using a trade name for a biosimilar may be desirable by companies to establishing brand building, the name method is hard to implement in China because they may violate the current prescription management measures outlined by the Ministry of Health of the People’s Republic of China. The authors argued that a more mature policy environment for biosimilars may need to be established.
Additionally, the authors stressed that incentive policies, such as reimbursement opportunities, are essential to ensure market fairness and access. Prices should be set reasonably and be based on the research and development investment.
"Whether in China or European or American countries, greater price reduction may be the problem that biosimilar drugs need to address directly,” the authors wrote.
Because the Chinese biosimilar market is in its early stages, the authors expressed that physicians should be the sole decision makers on which product patients should be prescribed, recommending that China should hold off on granting interchangeability to biosimilars.
Finally, the authors said that China should establish a biosimilar catalog to encourage biosimilar development and provide information for the general public and health care professionals. The catalog should include approval information, designated reference drugs, and data protection information of the originator.
Reference
Yang J, Zhao X, Li J, et al. Creating China’s biosimilar drugs regulatory system: a calculated approach. Front Pharmacol. Published online February 2, 2023. doi:10.3389/fphar.2022.815074
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.